CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T Lymphoblastic Leukemia/Lymphoma Clinical Trial

Official title:

Study of CD7 CAR-T Cells in Adult Refractory and Recurrent T-cell Lymphoma/Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05620680
• Other study ID #: HEM-ONCO-017
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2022
• Est. completion date: October 31, 2028

Study information

• Verified date: November 2022
• Source: Shenzhen University General Hospital
• Contact: Yu Li, Dr
• Phone: +8675521839178
• Email: liyu[@]vip.163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.

In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.

Description:

T-cell lymphoma accounts for 10%~15% of non-Hodgkin lymphoma in China. According to the World Health Organization (WHO), T-cell lymphoma was divided into the following subtypes: T-cell, NK cell lymphoma/leukemia. There were two major categories: anterior T-cell tumors and posterior thymic T-cell lymphomas, which originate from lymph nodes, extranodal tissue, or skin; mature or peripheral T-cell lymphomas.

Generally speaking, the relapse accounts for 50-60% after first-line treatment, while the remission rate with second-line treatment was extremely low. Collectively, there was an urgent need for new treatment modalities to improve the clinical outcomes of these patients.

CD7 is a transmembrane glycoprotein that plays an important role in T-cell and T-cell/B-cell interactions during early lymphoid development. The expression of CD7 persist from stem to mature T cells. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.

In this study we aim to testify the safy and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 31, 2028
• Est. primary completion date: October 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 (= 18 years old, = 75 years old), gender is not limited;

2. The subject voluntarily participates in the research and signs the "Informed Consent" by himself or his legal guardian;

3. According to the National Comprehensive Cancer Network (NCCN) T lymphocytic lymphoma (2020.V1)/acute lymphoblastic leukemia (2020. V1) practice guidelines, diagnosed with T-cell lymphoma;

4. Meet the diagnostic criteria for relapsed/refractory T-cell lymphoma, including any of the following:

1) Failure to obtain CR at the end of induction therapy; 2) Patients who have obtained CR have blasts in peripheral blood or bone marrow (proportion >5%), or extramedullary diseases; 5. Have not received antibody therapy within 2 weeks before cell therapy; 6. ECOG score of 0-2; 7. The subject has no contraindications to peripheral apheresis; 8. Expected survival time of more than 3 months.

Exclusion Criteria:

1. Those who have a history of allergy to any of the ingredients in cell products;

2. Laboratory tests for the following: including but not limited to, total serum bilirubin? 1.5mg/dl; Serum ALT or AST greater than 2.5 times the upper limit of normal; Blood creatinine? 2.0mg/dl; Platelet count? 10×109/L;

3. Patients with cardiac insufficiency who belong to class III or IV according to the New York Cardiology Association (NYHA) cardiac function grading standards; or echocardiography with left ventricular ejection fraction (LVEF) < 50%;

4. Abnormal lung function, blood oxygen saturation under indoor air < 92%;

5. Myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other serious clinical heart disease within 12 months before enrollment;

6. Grade 3 hypertension with poor control of blood pressure with medication;

7. Patients with other advanced tumors (those who are assessed as stable after treatment of other tumors can be enrolled);

8. Previous head trauma, impaired consciousness, epilepsy, more serious cerebral ischemia or cerebral hemorrhage disease;

9. Known central nervous system leukemia (CNS2 or CNS3), resistance to intrathecal chemotherapy injections and/or ongoing head and/or spinal radiation therapy; Previous CNS history but has been effectively controlled to allow enrollment;

10. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressant therapy;

11. presence of uncontrolled, active infection;

12. Have previously used any CAR-T cell product or other genetically modified T cell therapy;

13. Live vaccination within 4 weeks prior to enrollment;

14. HIV, HBV, HCV and TPPA/RPR infections, and HBV carriers;

15. Subject has a history of alcoholism, drug addiction or mental illness;

16. The subject has participated in any other clinical research within 3 months before joining this clinical study;

17. Female subjects have any of the following conditions: a) are pregnant/lactating; or b) have plans to become pregnant during the trial; or c) are of childbearing potential and unable to use effective contraception;

18. There are other circumstances in which the investigator believes that the subject is not suitable for this study.

Related Conditions & MeSH terms

• Leukemia
• Lymphoma
• Lymphoma, T-Cell
• T Lymphoblastic Leukemia/Lymphoma

Intervention

Biological:
• CD7 CAR-T cells
patient was subjected to 0.5-2×10^6 cells/kg of CD7 CAR- T

Locations

Country	Name	City	State
China	Li Yu	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen University General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TEAEs	Adverse events during treatment	From date of initial treatment to the 30 days after treatment
Secondary	overall response rate	the proportion of complete and partial response patients	baseline and 8 weeks, up to 1 year